Hexaom (ALHEX)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 21.70 |
|---|---|
| 52-week range | 19.90 – 35.64 |
| Return, 1 month / 3 months | +0.9% / −20.2% |
| Return, 1 year / 3 years | −22.1% / +55.2% |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 38.9% |
| Worst drawdown (1 year) | -43.0% |
| Average daily value traded | 0.20M EUR |
| Dividend yield | 3.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hexaom is a French construction group that builds new houses, chiefly detached single-family homes for individual buyers, and it also carries out renovation work and related building services through its subsidiaries. The company works with private customers across France, handling projects from design and planning through construction, and it operates a network of local branches and brands serving households who want to build or improve their own home.
On this site Hexaom appears as a stock on the Euronext Paris (France), code ALHEX, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hexaom (ALHEX) trades on the Euronext Paris in France. It last closed at EUR 21.70 on 19 October 2026.
Its price-based Market X-Ray is 35 out of 100 (a weak price profile), ranking 468 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 22.1% and over the last three months it fell 20.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 22 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -26.7% | ||
| From 52-week high | -38.8% | ||
| Momentum | 22 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -20.2% | ||
| 6-month return | -35.2% | ||
| 12-month return, skipping the last month | -22.8% | ||
| Stability (higher is calmer) | 44 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -43.0% | ||
| Liquidity | 69 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.20M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 30 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.7% | ||
| Years with dividends | 3 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.9% |
|---|---|
| 1 month | +0.9% |
| 3 months | −20.2% |
| 6 months | −35.2% |
| 1 year | −22.1% |
| 3 years | +55.2% |
| 5 years | −43.4% |
Signals
| 50-day / 200-day average | 23.95 / 29.61 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.99 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Jul 2026 | EUR 0.8000 |
| 1 Jul 2025 | EUR 0.4900 |
| 14 Jun 2022 | EUR 1.4100 |
| 8 Jun 2021 | EUR 1.1700 |
| 11 Jun 2019 | EUR 1.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.